Which girls bought last year...last year was a warm winter, so was year before...this is pent up demand given the severe winter this year.
UGGs out of style ? I am in warm california and see a whole bunch of people wearing UGGS.
Solid growth in both EPS and Rev, and someone is saying UGGs are out of style ??
For Jan 2013 earnings they had rev of $617M and EPS of 2.77...still much lower than what is expected to be reported Jan 2014.
now they are expecting $709M / EPS 3.77....stock is at $84 ?
how do you know that ?
We think it's just early enough in the season after 2 mild winters to still be cautious at this point in time with that assumption.
Plus they are expecting 100 points gross margin improvment due to PURE UGG sheepskin.
I think Q4 and FY14 are going to be killer for DECK.
this EPS is way too low I think. It has not been estimated up yet.
Once again bodes VERY well for DECK...DECK is all outdoors winter for UGGs. SKX said the same yesterday.
Sales at the outdoor and action sports segment, the largest contributor to revenue, jumped 12% to $1.92 billion as it posted double-digit sales growth in its Vans, North Face and Timberland brands. In its jeans business, sales ticked down to $734.1 million from $734.8 million.
sounds like DECK is going to be very well at earnings -
With our broad assortment of products, we weathered the unseasonably cold winter in the Midwest and Northeast thanks to one of our strongest boot collections, and the unseasonably warm weather in the West thanks to one of our strongest Sport collections.
National Weather Service warning of 8 to 16 inches accumulating by Friday morning and near white-out conditions at times.
if they come up with a buy now, stock will pop to mid 90s.
for DECK. A LOT of upgrades last 2 months with price targets $110 average.
This earnings is for Oct, Nov, Dec. Should see a big increase in guidance for Jan, Feb Mar qtr too given the severe winter in US still in progress.
The conference is NOT going to give any new news. C'mon, these trials takes many quarters to complete to give any updates. They JUST started the PH 3 and the other PH 2s. Nothing new will come from a 1/2 hr presentation.
Plus with valuation now close to $400M, stock is overvalued for now...
potential is there..but not a good buy at this price.
CytRx recently reported that, of the 11 patients enrolled in the STAR-1 trial to date, three (27%) achieved a hematologic complete response, and four (36%) a morphologic leukemia-free state. Based on the preliminary results in the clinical trial for third-line APL, CytRx has announced its intention to work with key opinion leaders to design a clinical trial to evaluate tamibarotene in combination with other agents as a first-line treatment for this cancer. CytRx holds the North American and European rights to tamibarotene as a treatment for APL. The FDA has granted Orphan Drug Designation for APL and Fast Track Designation for the use of tamibarotene in patients with relapsed or refractory APL following treatment with all-trans retinoic acid (ATRA) and arsenic trioxide. In addition, tamibarotene has been granted orphan medicinal product status by the European Medicines Agency for the treatment of APL. The efficacy of orally-administered tamibarotene was demonstrated in two Phase 2 studies conducted in Japan in a total of 63 Japanese subjects with APL. The overall complete response rate in these subjects was 60%. In subjects experiencing their first relapse, the overall complete response rate was 81%.
Tells us the potential of CYTR...this is not Aldo..so they have a lot of solid drugs in pipeline. FDA coming soon...
Along with his parents and faith, modern medicine helped save Ray Johnston’s life. At one point in time, Ray had 26 doctors working with him. He took an experimental drug called Tamibarotene that is now in second phase clinical trials. The sheer number of talented people working with him made Ray want to win – in this case, beat the cancer.
at least to 77-78 IMO.
can someone help. thanks !